| Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease C Ma, MD Sacco, B Hurst, JA Townsend, Y Hu, T Szeto, X Zhang, ... Cell research 30 (8), 678-692, 2020 | 778 | 2020 |
| Structure and inhibition of the SARS-CoV-2 main protease reveal strategy for developing dual inhibitors against Mpro and cathepsin L MD Sacco, C Ma, P Lagarias, A Gao, JA Townsend, X Meng, P Dube, ... Science Advances 6 (50), eabe0751, 2020 | 353 | 2020 |
| Structure and inhibition of the drug-resistant S31N mutant of the M2 ion channel of influenza A virus J Wang, Y Wu, C Ma, G Fiorin, J Wang, LH Pinto, RA Lamb, ML Klein, ... Proceedings of the National Academy of Sciences 110 (4), 1315-1320, 2013 | 257 | 2013 |
| Ebselen, disulfiram, carmofur, PX-12, tideglusib, and shikonin are nonspecific promiscuous SARS-CoV-2 main protease inhibitors C Ma, Y Hu, JA Townsend, PI Lagarias, MT Marty, A Kolocouris, J Wang ACS pharmacology & translational science 3 (6), 1265-1277, 2020 | 236 | 2020 |
| Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19 B Boras, RM Jones, BJ Anson, D Arenson, L Aschenbrenner, ... Nature communications 12 (1), 6055, 2021 | 221 | 2021 |
| Functional studies indicate amantadine binds to the pore of the influenza A virus M2 proton-selective ion channel X Jing, C Ma, Y Ohigashi, FA Oliveira, TS Jardetzky, LH Pinto, RA Lamb Proceedings of the National Academy of Sciences 105 (31), 10967-10972, 2008 | 218 | 2008 |
| Identification of the functional core of the influenza A virus A/M2 proton-selective ion channel C Ma, AL Polishchuk, Y Ohigashi, AL Stouffer, A Schön, E Magavern, ... Proceedings of the National Academy of Sciences 106 (30), 12283-12288, 2009 | 185 | 2009 |
| Molecular dynamics simulation directed rational design of inhibitors targeting drug-resistant mutants of influenza A virus M2 J Wang, C Ma, G Fiorin, V Carnevale, T Wang, F Hu, RA Lamb, LH Pinto, ... Journal of the American Chemical Society 133 (32), 12834-12841, 2011 | 163 | 2011 |
| Discovery of SARS-CoV-2 papain-like protease inhibitors through a combination of high-throughput screening and a FlipGFP-based reporter assay C Ma, MD Sacco, Z Xia, G Lambrinidis, JA Townsend, Y Hu, X Meng, ... ACS central science 7 (7), 1245-1260, 2021 | 138 | 2021 |
| Expedited approach toward the rational design of noncovalent SARS-CoV-2 main protease inhibitors N Kitamura, MD Sacco, C Ma, Y Hu, JA Townsend, X Meng, F Zhang, ... Journal of medicinal chemistry 65 (4), 2848-2865, 2021 | 132 | 2021 |
| Discovery of novel dual inhibitors of the wild-type and the most prevalent drug-resistant mutant, S31N, of the M2 proton channel from influenza A virus J Wang, C Ma, J Wang, H Jo, B Canturk, G Fiorin, LH Pinto, RA Lamb, ... Journal of medicinal chemistry 56 (7), 2804-2812, 2013 | 119 | 2013 |
| Discovery of a novel inhibitor of coronavirus 3CL protease for the potential treatment of COVID-19 B Boras, RM Jones, BJ Anson, D Arenson, L Aschenbrenner, ... BioRxiv, 2020.09. 12.293498, 2020 | 118 | 2020 |
| Discovery of di-and trihaloacetamides as covalent SARS-CoV-2 main protease inhibitors with high target specificity C Ma, Z Xia, MD Sacco, Y Hu, JA Townsend, X Meng, J Choza, H Tan, ... Journal of the American Chemical Society 143 (49), 20697-20709, 2021 | 109 | 2021 |
| Flipping in the pore: discovery of dual inhibitors that bind in different orientations to the wild-type versus the amantadine-resistant S31N mutant of the influenza A virus M2 … Y Wu, B Canturk, H Jo, C Ma, E Gianti, ML Klein, LH Pinto, RA Lamb, ... Journal of the American Chemical Society 136 (52), 17987-17995, 2014 | 94 | 2014 |
| The amphipathic helix of influenza A virus M2 protein is required for filamentous bud formation and scission of filamentous and spherical particles KL Roberts, GP Leser, C Ma, RA Lamb Journal of virology 87 (18), 9973-9982, 2013 | 91 | 2013 |
| Exploring the size limit of templates for inhibitors of the M2 ion channel of influenza A virus MD Duque, C Ma, E Torres, J Wang, L Naesens, J Juárez-Jiménez, ... Journal of medicinal chemistry 54 (8), 2646-2657, 2011 | 87 | 2011 |
| pH-induced conformational change of the influenza M2 protein C-terminal domain PA Nguyen, CS Soto, A Polishchuk, GA Caputo, CD Tatko, C Ma, ... Biochemistry 47 (38), 9934-9936, 2008 | 86 | 2008 |
| Boceprevir, calpain inhibitors II and XII, and GC-376 have broad-spectrum antiviral activity against coronaviruses Y Hu, C Ma, T Szeto, B Hurst, B Tarbet, J Wang ACS infectious diseases 7 (3), 586-597, 2021 | 82 | 2021 |
| Rational design of hybrid SARS-CoV-2 main protease inhibitors guided by the superimposed cocrystal structures with the peptidomimetic inhibitors GC-376, telaprevir, and boceprevir Z Xia, M Sacco, Y Hu, C Ma, X Meng, F Zhang, T Szeto, Y Xiang, Y Chen, ... ACS pharmacology & translational science 4 (4), 1408-1421, 2021 | 81 | 2021 |
| Expeditious lead optimization of isoxazole-containing influenza A virus M2-S31N inhibitors using the Suzuki–Miyaura cross-coupling reaction F Li, Y Hu, Y Wang, C Ma, J Wang Journal of medicinal chemistry 60 (4), 1580-1590, 2017 | 77 | 2017 |
Jun WangRutgers, the State University of New Jersey在 pharmacy.rutgers.edu 的电子邮件经过验证
